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Abstract
Background:  Gene transfer to nociceptive neurons of the dorsal root ganglia (DRG) is a
promising approach to dissect mechanisms of pain in rodents and is a potential therapeutic strategy
for the treatment of persistent pain disorders such as neuropathic pain. A number of studies have
demonstrated transduction of DRG neurons using herpes simplex virus, adenovirus and more
recently, adeno-associated virus (AAV). Recombinant AAV are currently the gene transfer vehicles
of choice for the nervous system and have several advantages over other vectors, including stable
and safe gene expression. We have explored the capacity of recombinant AAV serotype 6 (rAAV2/
6) to deliver genes to DRG neurons and characterized the transduction of nociceptors through five
different routes of administration in mice.
Results: Direct injection of rAAV2/6 expressing green fluorescent protein (eGFP) into the sciatic
nerve resulted in transduction of up to 30% eGFP-positive cells of L4 DRG neurons in a dose
dependant manner. More than 90% of transduced cells were small and medium sized neurons (<
700 m2), predominantly colocalized with markers of nociceptive neurons, and had eGFP-positive
central terminal fibers in the superficial lamina of the spinal cord dorsal horn. The efficiency and
profile of transduction was independent of mouse genetic background. Intrathecal administration
of rAAV2/6 gave the highest level of transduction ( 60%) and had a similar size profile and
colocalization with nociceptive neurons. Intrathecal administration also transduced DRG neurons
at cervical and thoracic levels and resulted in comparable levels of transduction in a mouse model
for neuropathic pain. Subcutaneous and intramuscular delivery resulted in low levels of
transduction in the L4 DRG. Likewise, delivery via tail vein injection resulted in relatively few eGFP-
positive cells within the DRG, however, this transduction was observed at all vertebral levels and
corresponded to large non-nociceptive cell types.
Conclusion:  We have found that rAAV2/6 is an efficient vector to deliver transgenes to
nociceptive neurons in mice. Furthermore, the characterization of the transduction profile may
facilitate gene transfer studies to dissect mechanisms behind neuropathic pain.
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Background
Chronic pain, and in particular, neuropathic pain, is a
common condition that greatly impacts on individual
quality of life and places considerable burden on the
healthcare system as well as society [1,2]. Current phar-
macological agents used for treating chronic pain act
mainly through analgesic mechanisms not specific to the
intrinsic pathways of pain and are prone to elicit side
effects. An intricate understanding of the cellular mecha-
nisms and pathways contributing to pain would therefore
greatly facilitate the development of novel therapeutics
towards a mechanisms-based pain management.
Gene transfer to primary sensory neurons within the noci-
ceptive pathway is a novel approach to study pain. Trans-
genes of interest can be expressed in adult animals in
order to dissect their roles within pain signaling pathways
and are an alternative to transgenic approaches. Gene
transfer to nociceptors is also a promising strategy for the
management of chronic pain, allowing expression of a
transgene at restricted sites in the nervous system there-
fore selectively targeting pain-related pathways without
eliciting off-target effects.
Gene transfer to nociceptive neurons has been achieved
through both viral and non-viral methods. Plasmid DNA
driving expression of proteins have been delivered to sen-
sory neurons via liposomes [3], electroporation [4] and
delivery through hypertonic diluent [5] through periph-
eral or direct injections to the central nervous system. The
major drawback of these methods is that they result in
transient protein expression persisting no longer than two
weeks. Alternatively, viruses can be used to drive longer
transgene expression. The efficacy of viral-mediated gene
delivery depends primarily on the type of delivery method
and the type of virus being used. Adenovirus, herpes-sim-
plex virus (HSV), lentivirus and adeno-associated virus
(AAV) have been reported to deliver transgenes to nocice-
ptive pathways through a number of delivery routes
including subcutaneous [6], intramuscular [7], intraneu-
ral [8], intrathecal [9,10], intraspinal [11,12], direct dorsal
root ganglia injections [13] and also topical applications
of the virus in the case of HSV [14,15]. While these studies
have resulted in transgene expression at favorable sites
and with concomitant reduction in pain-related behavior,
the transduction profile has not often been characterized.
This is common in studies that utilize secreted transgenes
that act in the extracellular environment, such as enkepha-
lin, endomorphins and interleukins, where only a few
transduced cells are required to deliver the transgene to
the affected cellular neighborhood and modulate pain
perception [16].
The aim of this study was to assess recombinant AAV
(rAAV) serotype 6 as a gene transfer tool to target cellular
mechanisms involved in the generation and development
of chronic pain in mice. rAAVs are powerful gene transfer
vectors due to their broad tissue tropism, efficient and sta-
ble transduction (> years), poor immunogenicity and
ability to infect post-mitotic cells in vivo [17]. The serotype
6 vector (rAAV2/6) was chosen from the observation of
sensory fiber transduction following intravenous delivery
in previous experiments in mice [18] and the high tro-
pism for neurons following direct injections into the cen-
tral nervous system [19]. In the present study, we have
delivered this vector through various routes of administra-
tion and precisely mapped and compared the transduc-
tion profiles obtained within the dorsal root ganglia
(DRG) and spinal cord.
Results
rAAV2/6 transduces dorsal root ganglia and is dependant 
upon mode of delivery
rAAV2/6 (rAAV serotype 2 genome packaged in the sero-
type 6 capsid) was delivered to C57BL/6 mice through
four routes; subcutaneously at the middle and lateral
plantar surface of the hind foot; intramuscularly in the tri-
ceps surae muscle of the hind limb; in the sciatic nerve;
and intrathecally at the lumbar level. Three different doses
of vector were examined (except for the intrathecal
administration which received only the high dose) and
the transduction was assessed three weeks later. All modes
of delivery resulted in eGFP epifluorescence within the
whole dissected L4 DRG demonstrating that rAAV2/6 is
capable of transducing sensory neurons (Fig. 1A, 1B). The
levels of transduction were dependant upon the mode of
delivery (from highest to lowest) with intrathecal, sciatic
nerve, subcutaneous and intramuscular delivery resulting
in 57.5 ± 0.1, 28.1 ± 3.1, 3.5 ± 1.7 and 1.6 ± 0.6 percent of
eGFP expressing profiles per total number of DRG cells
observed, respectively. Furthermore, the transduction rate
was dose dependent in instances where examined (Fig.
1C).
The relative transduction efficiencies for the various deliv-
ery routes were next assessed by quantifying the vector
genome copy numbers per cell (vg/cell) following injec-
tion of the high dose of vector. Intrathecal administration
resulted in the highest level of vector genomes in DRG (L4
+ L5 combined) (9.2 ± 3.5 vg/cell), with sciatic nerve and
subcutaneous delivery providing lower copy numbers
(1.7 ± 0.6 vg/cell and 1.0 ± 0.5 vg/cell, respectively) (Fig.
1D). Vector genomes were not detected following intra-
muscular delivery. Intrathecal delivery also resulted in the
presence of vector genomes in the lumbar spinal cord (0.8
± 0.1 vg/cell) and gave the highest numbers of vector
genomes in the liver (2.3 ± 0.6 vg/cell). Liver transduction
is typical for rAAV2/6 and reflects leakage of the vector
from the injection site into the blood. Interestingly, only
the sciatic nerve injection failed to register vector genomesMolecular Pain 2009, 5:52 http://www.molecularpain.com/content/5/1/52
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Figure 1 (see legend on next page)Molecular Pain 2009, 5:52 http://www.molecularpain.com/content/5/1/52
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in the liver demonstrating the specificity of this injection
technique.
Reverse transcription quantitative PCR (qPCR) against
eGFP mRNA transcripts recapitulated this transduction
profile. mRNA transcripts for eGFP were approximately
seven times more abundant for intrathecal than sciatic
nerve delivery in lumbar DRG (Fig. 1E). Subcutaneous
delivery resulted in approximately one third of transcripts
compared to sciatic nerve delivery and intramuscular
administration failed to result in detectable levels of eGFP
mRNA. Curiously, despite the presence of vector genomes
in spinal cord and liver observed above, we did not detect
any eGFP mRNA expression in these two tissues regardless
of the delivery route (not shown).
Efficient transduction of nociceptive neurons following 
sciatic nerve and intrathecal injections
We next characterized the transduction profile of the most
efficient administration routes, the sciatic nerve and
intrathecal deliveries. As primary sensory neurons in mice
represent a diverse cell population that can be classified
according to size [20]; small C-fiber polymodal nocicep-
tive neurons < 300 m2, medium-sized A-fiber thermal
and mechanical nociceptive neurons between 300 and
700 m2, and large A-fiber mechanoreceptive neurons
and A-fiber proprioceptive neurons > 700 m2, we have
determined the distribution of cell size (m2) for the
eGFP-positive cells in relation to the total eGFP-positive
cell population (Fig. 2A, 2B). Greater than 90% of eGFP-
positive cell sizes corresponded to small to medium-sized
cell types (<700 m2) for sciatic nerve and intrathecal
injection (Fig. 2C) suggesting transduction of nociceptive
neurons.
Immunohistochemistry was next performed to further
characterize the vector tropism for putative nociceptive
neurons. L4 DRG sections were labeled with antibodies
against markers of various neuronal populations and
assessed for colocalization with eGFP (Fig. 3, 4). More
eGFP-positive cells colocalized with transient receptor
potential vanilloid 1 (TRPV1) than with neurofilament
200 (NF200) for both modes of delivery. Indeed NF200
colocalization with eGFP was rare, although, interest-
ingly, was more frequent for the intrathecal than the sci-
atic nerve delivery. There was also colabeling with markers
of the small peptidergic neurons, Substance P, -calci-
tonin gene-related peptide (CGRP) and neurotrophic
tyrosine kinase receptor type 1 (TrkA) and the non-pepti-
dergic neuronal population, isolectin B4 (IB4) for both
modes of delivery.
The pattern of eGFP visualization within the spinal cord
recapitulated this transduction of putative nociceptive
neurons. eGFP-immunoreactive fibers were located
almost exclusively within the superficial lamina I and II of
the dorsal horn following sciatic nerve and intrathecal
injections whereas subcutaneous and intramuscular
administration transduced central terminals of DRG neu-
rons within deeper laminae (Fig. 5A, 5B). Curiously, the
transduced fibers following sciatic nerve delivery colocal-
ized extensively with CGRP1 suggesting an enriched trans-
duction of peptidergic neurons following this delivery
route.
As glial cells have recently emerged as key contributors to
chronic pain mechanisms [21], we examined whether sci-
atic nerve and intrathecal deliveries resulted in transduc-
tion of astrocytes and microglia in the spinal cord dorsal
horn. No colocalization was observed with glial cell mark-
ers glial fibrillary acidic protein (GFAP; astrocytes) nor
ionized calcium binding adaptor molecule 1 (Iba1;
microglia). Similarly, the transduction of satellite cells
within the DRG was not observed (see additional file 1:
satellite and glial cells.tif). Large eGFP-positive cells (> 25
m) were observed within the ventral horn and possibly
corresponded to transduction of motor neurons via retro-
grade transport from the nerves (see additional file 2:
eGFP anterior horn.tif).
rAAV2/6 transduction of the dorsal root ganglia following subcutaneous, intramuscular, sciatic nerve and intrathecal delivery Figure 1 (see previous page)
rAAV2/6 transduction of the dorsal root ganglia following subcutaneous, intramuscular, sciatic nerve and 
intrathecal delivery. (A) Macroscopic view of L4 DRG of mice injected with rAAV2/6 expressing eGFP. From left to right: 
uninjected, dose response of sciatic nerve injected, subcutaneous (high dose), intramuscular (high dose), intrathecal (high 
dose). (B) Native eGFP expression and corresponding bright field image in a typical 12 m L4 DRG section following sciatic 
nerve delivery. Scale bar, 100 m. (C) Transduction rates within L4 DRG following subcutaneous, intramuscular, sciatic nerve 
delivery at three doses (n = 3 per group and dose) and intrathecal delivery at the highest dose (n = 5) expressed as a percent-
age of eGFP expressing profiles per total number of DRG cells observed. LD, low dose (2.6 × 104 tu); MD, medium dose (8.0 × 
104 tu); HD, high dose (2.6 × 105 tu). (D) qPCR against the vector genome (beta globin intron of rAAV2/6) in DRG, spinal cord 
and liver for the high dose of the four administration routes. (E) Reverse transcription qPCR against eGFP mRNA transcripts 
normalized with GAPDH mRNA in the DRG for the various protocols.Molecular Pain 2009, 5:52 http://www.molecularpain.com/content/5/1/52
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Cell-size profile of eGFP-positive neurons in the L4 DRG following sciatic nerve and intrathecal injection Figure 2
Cell-size profile of eGFP-positive neurons in the L4 DRG following sciatic nerve and intrathecal injection. (A) 
eGFP-positive neurons classified into small-sized (< 300 m2, black bars), medium-sized (300-700 m2, grey bars) and large-
sized (>700 m2, white bars) for the three doses of sciatic nerve injection and the intrathecal injection. Cell-size frequency his-
togram for eGFP-positive cell population three weeks following sciatic nerve (B) (n = 3, 858 eGFP-positive neurons measured) 
and intrathecal injection (C) (n = 5, 3146 eGFP-positive neurons measured) of 2.6 × 105 tu rAAV2/6.Molecular Pain 2009, 5:52 http://www.molecularpain.com/content/5/1/52
Page 6 of 17
(page number not for citation purposes)
Neuronal transduction pattern following sciatic nerve injection Figure 3
Neuronal transduction pattern following sciatic nerve injection. Representative confocal images demonstrating colo-
calization of eGFP-positive neurons with markers against neuronal subpopulations following injection of 2.6 × 105 tu rAAV2/6 
into the sciatic nerve. TRPV1, Substance P, CGRP and TrkA for small peptidergic neurons, IB4 for non-peptidergic neurons and 
NF200 for large neurons. Scale bar: 100 m.Molecular Pain 2009, 5:52 http://www.molecularpain.com/content/5/1/52
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Neuronal transduction pattern following intrathecal injection Figure 4
Neuronal transduction pattern following intrathecal injection. Representative confocal images demonstrating colocal-
ization of eGFP-positive neurons in L4 DRG with markers against primary sensory neurons subpopulations following injection 
of 2.6 × 105 tu rAAV2/6 into the subarachnoid space. Scale bar: 100 m.Molecular Pain 2009, 5:52 http://www.molecularpain.com/content/5/1/52
Page 8 of 17
(page number not for citation purposes)
Transduction of sensory fibers within the dorsal horn following rAAV2/6 delivery via different routes Figure 5
Transduction of sensory fibers within the dorsal horn following rAAV2/6 delivery via different routes. (A) eGFP 
expression in dorsal horn following sciatic nerve, subcutaneous, intramuscular, and intrathecal injection of 2.6 × 105 tu rAAV2/
6. Scale bar: 100 m. Confocal microscope images for CGRP (red, lamina I and II outer) and IB4 (blue, lamina II inner) against 
eGFP expression (green) in the dorsal horn following sciatic nerve (B) and intrathecal (C) injection. Scale bar: 50 m.Molecular Pain 2009, 5:52 http://www.molecularpain.com/content/5/1/52
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Intrathecal administration of rAAV2/6 results in 
transduction at remote sites within the nervous system and 
periphery of mice
Considering the unexpected observation that intrathecal
delivery of rAAV2/6 resulted in relatively high levels of
vector genomes in the liver (Fig. 1D), we next character-
ized the global spread of the vector following this mode of
administration. Macroscopic analysis of eGFP epifluores-
cence from whole dissected spinal cord and DRG revealed
significant transduction across the breadth of the rostral-
caudal axis (Fig. 6A, 6B). Lumbar DRG were the most
strongly transduced with peak transduction consistently
occurring at L1 and L2 (n = 6). Surprisingly, cervical DRG
expressed higher levels of eGFP-positive cells than the tho-
racic DRG which contained few eGFP-positive cells. qPCR
against the vector genomes confirmed this transduction
profile, with cervical, thoracic and lumbar DRG contain-
ing 3.3 ± 1.8, 0.4 ± 0.2 and 5.3 ± 2.0 vg/cell, respectively
(Fig. 6C). The spinal cord and most of the regions of brain
also contained the presence of vector genomes, although
considerably less than the DRG (< 1 vg/cell) (Fig. 6D).
Interestingly, the leptomeningeal cells that are bathed in
the cerebrospinal fluid did not express eGFP (Fig. 6E). All
peripheral tissues examined (except for the liver) con-
tained negligible levels of vector genome (< 0.2 vg/cell)
(Fig. 6F).
DRG transduction efficiency is not altered in the SNI 
mouse model of neuropathic pain
In order to determine whether rAAV2/6-mediated gene
transfer was applicable in mouse models of neuropathic
pain, C57Bl/6 mice were intrathecally injected with the
vector three days following nerve ligation in the spared
nerve injury (SNI) model (n = 3 per group). No significant
difference was observed between groups with sham and
SNI-treated animals presenting 37 ± 8 and 48 ± 3 percent
of eGFP-positive cells per total cell number in L4 and L5
DRG, respectively (P = 0.52) (see additional file 3: SNI
transduction.tif). This finding demonstrates that rAAV2/6
can be used as a gene transfer tool in mechanistic studies
for chronic pain.
Mouse genetic background does not alter tropism of 
vector for nociceptive neurons
The vector was administered to different strains of mice to
determine whether the rAAV2/6 nociceptive neuron tro-
pism was dependant on the genetic background of the
host. C57Bl/6, SJL and B6SJLF1 mice were injected into
the sciatic nerve with the high dose of rAAV2/6 and sacri-
ficed three weeks later. eGFP expression was observed in
between 25 and 35% of the total cell population in the
DRG in accordance with previous results (Fig. 7A). There
was a trend for an increased transduction of the C57BL/6
compared to the B6SJLF1 background although this was
below significance (P = 0.087). The cell-size distribution
of eGFP-positive cells was similar between strains sup-
porting a consistent transduction profile (Fig. 7B). These
results suggest that the rAAV2/6 tropism for nociceptive
neurons is independent of mouse strain.
Intravenous delivery of rAAV2/6 results in transduction of 
non-nociceptive DRG neurons
Two reports have recently described transduction of fibers
within the dorsal spinal cord following intravenous
administration of rAAV [18,22]. To determine whether
this mode of delivery results in transduction of cells
within the DRG, we injected 1.2 × 107 tu rAAV2/6 into the
tail vein of C57BL/6 mice. Three weeks following intrave-
nous delivery we observed relatively low levels of eGFP
expression in the DRG at all levels of the spine (L4 DRG
shown in Fig. 8A). These cells colocalized predominantly
with NF200 (Fig. 8B) and not with peripherin (data not
shown). Similarly, only transduced fibers within the
deeper lamina of the spinal cord were observed (Fig. 8C).
Discussion
Although a considerable number of reports have
described the use of HSV and adenovirus as gene transfer
agents in the peripheral nervous system, both are derived
from disease-causing viruses that express structural pro-
teins capable of eliciting an immune response, invariably
leading to short-term gene expression (< 2 months) and
cytotoxicity [6,23,24]. rAAV is a non-inflammatory vector
that provides efficient and long-term expression in neu-
rons in vivo and whose parent wild-type virus has never
been associated with disease. In the present study, we have
examined the ability of rAAV serotype 6 to deliver a trans-
gene to the dorsal root ganglia of mice following five dif-
ferent routes of administration. We have carefully
estimated the percentage of cells transduced and charac-
terized the transduction profile in terms of cell size and
colocalization with neuronal markers. When combined or
compared with transgenic approaches, this vector may
provide valuable information in the mechanistic study of
pain.
The ability of rAAV2/6 to transduce sensory neurons from
the periphery was examined first as this vector has been
reported capable of retrograde axonal transport [18,25].
Delivery into the triceps surae muscle of the hindlimb
resulted in transduction of cells within the L4 DRG albeit
at low levels. The transduction may have arisen through
infection of intrafusal muscle fibers and Golgi tendon
organs that are located in the muscle and send proprio-
ceptive information to the spinal cord. This is in accord-
ance with the observation that eGFP-positive fibers were
located in the deeper lamina of the dorsal horn. Subcuta-
neous delivery of rAAV2/6 also resulted in low levels of
eGFP-positive neurons in the L4 DRG. Curiously, trans-
duction of the DRG following subcutaneous delivery hasMolecular Pain 2009, 5:52 http://www.molecularpain.com/content/5/1/52
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Global transduction profile following intrathecal delivery of rAAV2/6 Figure 6
Global transduction profile following intrathecal delivery of rAAV2/6. C57Bl/6 mice were intrathecally injected with 
2.6 × 105 tu rAAV2/6 and tissues analyzed for the vector dissemination. (A) Macroscopic epifluorescence of the whole spinal 
cord and intact DRG demonstrate transduction across lumbar, thoracic and cervical vertebral levels. (B) DRG were scored for 
eGFP expression (0 = zero, 1 = faint, 2 = weak, 3 = moderate and 4 = intense eGFP expression) (n = 6). qPCR analysis of vec-
tor genome copy number per cell in (C) DRG and (D) brain and spinal cord. (E) Native eGFP expression in spinal cord section 
containing intact meninges. eGFP is present in the dorsal horn and dorsal root but not within the subarachnoid space or mem-
branes of the pia mater and arachnoid. M, meninges, DH, dorsal horn, DR, dorsal root. Scale bar: 50 m. (F) qPCR against the 
rAAV2/6 genome in peripheral tissues.Molecular Pain 2009, 5:52 http://www.molecularpain.com/content/5/1/52
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not been observed previously for rAAV, with rAAV sero-
type 2 (rAAV serotype 2 genome packaged in the serotype
2 capsid, rAAV2/2) failing to transduce DRG cells follow-
ing subcutaneous injection into the hindpaw of rats [13].
This is not surprising as rAAV2/2 is inefficient at retro-
grade transport in comparison to rAAV2/6 [25].
Cutaneous and subcutaneous delivery of HSV has fre-
quently been used to transduce sensory neurons of rats
and mice as proof-of-principle for gene therapy of chronic
pain [16,26]. We cannot compare the transduction
observed here with previous reports as the vast majority
has not quantified transduction efficiency. This is in part
due to the use of secreted transgenic peptides that have
had the capacity to exert paracrine functions on non-
transduced cells. At least in one report, however, topical
delivery of HSV was shown to achieve approximately 50%
of total DRG neurons [15]. Despite the relatively lower
transduction observed in the present study, subcutaneous
delivery of rAAV2/6, with further optimization, may be an
alternative to HSV for the delivery of secreted transgenic
peptides towards human gene therapy of pain. Indeed,
rAAV is the only viral vector currently being examined in
clinical trials for neurological disease [27].
Transgene delivery to nociceptive neurons can also be
used to explore the nature of changes that lead to chronic
pain states. For example, HSV has been used to investigate
signaling pathways that result in altered ion channel func-
tions that have become hyper-responsive to channel acti-
vation and pain signaling [28]. Fink et al [29] have also
used HSV to examine the role of TNF signaling in
chronic pain. With the goal of increasing the number of
transduced nociceptive neurons that would be required
for exploring the mechanisms of pain, we examined sci-
atic nerve and intrathecal routes administration of rAAV
that have recently reported success in the transduction of
rat DRG. Indeed, injection of rAAV2/6 into the sciatic
nerve of C57BL/6 mice resulted in eGFP expression in
more than 30% of the L4 DRG neurons. This is a substan-
tial fraction of cells considering that the L4 DRG has affer-
ent projections into the sciatic nerve and also other nerves
of the lumbosacral plexus that were not injected (eg.
pudendal nerve, obturator nerve, posterior cutaneous
nerve of the thigh) that account for 40-50% of total L4/L5
DRG neurons [30]. Interestingly, the efficiency and profile
of transduction was similar for the three mouse strains
examined, suggesting that rAAV2/6 transduction of DRG
neurons can be applied to the mouse regardless of the
model being used.
The level of transduction observed in this study was simi-
lar to sciatic nerve delivery of rAAV2/2 in the rat
[13,31,32]. The serotype 6 rAAV used in the present report
has previously been delivered to the sciatic nerve of rats to
result in retrograde transport to motor neurons, however,
transduction in the DRG was not examined [25]. Other
viral vectors have also been examined through this deliv-
ery route. HSV has resulted in efficient transduction of the
L4 DRG, although declined dramatically after 3 weeks
[8,33,34]. Adenovirus has also been administered to the
sciatic nerve of rats and mice, although has led to trans-
duction of predominantly Schwann cells on both
accounts [35,36].
The cell-size profile of transduced cells was next character-
ized to determine whether nociceptors were efficiently tar-
geted. Approximately 90% of eGFP-positive cells were
small-sized (<300 m2) corresponding to putative nocic-
eptive neurons. As only one half the total DRG cell popu-
Genetic background does not affect rAAV2/6 neuronal tro- pism Figure 7
Genetic background does not affect rAAV2/6 neuro-
nal tropism. DRG transduction was assessed in C57Bl/6, 
SJL and B6SJLF1 mice following sciatic nerve injection of 2.6 × 
105 tu rAAV2/6. (A) Transduction rates within L4 DRG from 
the three different mice strains expressed as a percentage of 
eGFP-positive cells per total cell number (n = 3 per group). 
(B) Relative amounts of eGFP-positive neurons classified by 
somata size (small, medium, large).Molecular Pain 2009, 5:52 http://www.molecularpain.com/content/5/1/52
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lation of mice are less than 300 m2 [20], we can infer that
there was a transduction preference for this small nocice-
ptive cell population. Indeed, more frequent colocaliza-
tion of eGFP was observed with markers of small DRG
neurons (TRPV1, Substance P, CGRP, TrkA and IB4) than
with large neurons (NF200) in the DRG. eGFP-positive
fibers were present mainly in the superficial lamina of the
spinal cord and colocalized extensively with CGRP1 (lam-
ina I and II outer) and less with IB4 (lamina II inner) sug-
gesting an enriched transduction of peptidergic neurons
following this route of administration. Perhaps the appar-
ent transduction preference of nociceptors is attributed to
the degree of myelination that may impede entry of the
virion into larger fibers following injection into the nerve.
Further work would be required to confirm this.
Intrathecal administration into mice was next examined
as this has previously been reported to result in efficient
rAAV-mediated gene transfer to the DRG of rats [9,10]. To
negate the need of performing a laminectomy in the rela-
tively smaller rodent, a four centimeter catheter was
inserted into the cistern magna and moved to the level of
the lumbar spinal cord [37,38]. rAAV2/6 delivery resulted
in the highest transduction observed in the present study,
eGFP expression in DRG and spinal cord following intravenous delivery of rAAV2/6 Figure 8
eGFP expression in DRG and spinal cord following intravenous delivery of rAAV2/6. (A) eGFP expression in whole 
L4 DRG following intravenous injection of 1.2 × 107 tu rAAV2/6. Colocalization against NF200 (B) and eGFP expression in the 
deep lamina of the dorsal horn (C) demonstrate predominantly non-nociceptive transduction. Scale bar: 100 m.Molecular Pain 2009, 5:52 http://www.molecularpain.com/content/5/1/52
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reaching approximately 60% of L4 DRG neurons. eGFP-
positive cells colocalized with markers of nociceptive and
non-nociceptive cells, however, upon analysis of cell area,
there was a tendency for less small-sized neurons (<300
m2) (P = 0.15) and more medium-sized neurons (300 -
700 m2) (P = 0.18) than for the sciatic nerve delivery.
Importantly, we found that transduction efficiency was
unaltered following nerve ligation, demonstrating that
rAAV2/6 can be used in models of neuropathic pain.
The results observed here in mice are similar to that
obtained with rAAV serotype 8 (rAAV serotype 2 genome
packaged in the serotype 8 capsid) in rats, that led to high
levels of transduction of TRPV1, Substance P, CGRP and
IB4 positive cells within the DRG [10]. Curiously, rAAV2/
2 failed to transduce DRG cells following this mode of
delivery [13] demonstrating different cellular tropisms
among rAAV serotypes. Adenovirus has also been deliv-
ered intrathecally for chronic pain studies to result in effi-
cient (although transient) expression of proteins within
the cerebrospinal fluid, such as beta-endorphin [39] and
interleukin-10 [40], although transduction was not exam-
ined in the DRG.
Although intrathecal delivery results in transduction of
more DRG neurons, the sciatic nerve injection still has
advantages for studies of neuropathic pain. Unlike
intrathecal administration, injection of the sciatic nerve
can be performed unilaterally, which allows the non/vehi-
cle-treated side to serve as a useful internal control for
behavior or histology. This specificity of the nerve injec-
tion is further exemplified by the finding that only this
injection delivery route failed to result in spread of the
vector into the blood stream, whereas intrathecal admin-
istration gave considerable transduction in the liver.
Direct nerve injection can also be used to target injured
versus non-injured nerves, for example, in the spared
nerve injury model [41], where the spread of rAAV2/6 fol-
lowing intrathecal delivery would preclude this. Intrathe-
cal administration may therefore be more suited to
behavioral studies where the greater number of cells trans-
duced may allow better discrimination of changes to pain
perception in the whole animal.
Intravenous administration via the tail vein was also
examined as this had previously resulted in transgene
expression in the fibers of the spinal cord dorsal horn with
rAAV2/8 [22] and rAAV2/6 [18]. This mode of delivery
resulted in eGFP-positive cells within the DRG at lumbar,
thoracic and cervical levels of spinal cord, and colocalized
with the marker of non-nociceptive neurons, NF200. This
novel mode of transduction may have resulted through
infection of nerve endings within the muscle. This follows
the reasoning that 1) skeletal muscle is highly vascular-
ized and 2) the transduction pattern in the deeper lamina
of the spinal cord is similar to that observed after intra-
muscular rAAV2/6 delivery.
One caveat of this study has been that eGFP expression
was examined only at the designated three week time
point. Previously we have reported expression in neurons
at least 8 weeks following injection with the rAAV2/6 vec-
tor [19] and also observed stable expression for at least 5
months in spinal cord motor neurons (unpublished
observations). Taken together with the multitude of stud-
ies demonstrating long-term transgene expression for
rAAV in neurons, we believe that the rAAV2/6-mediated
transgene expression in nociceptive neurons would also
be stable through time.
Conclusion
We have examined rAAV2/6-mediated in vivo gene transfer
to neurons of mouse DRG through five routes of delivery.
Not only have we matched transduction efficiencies
achieved with other vectors, but we have mapped the
transduction profiles in terms of cell-size, cell marker
expression and fiber localization within the spinal cord.
We propose that rAAV2/6 is an efficient gene transfer tool
in rodents that can be used for the mechanistic study and
targeted molecular evaluation of proteins in the area of
neuropathic pain. Furthermore, the diversity of transduc-
tion depending upon mode of delivery can be exploited to
differentially target mechanisms in primary sensory neu-
ron populations.
Materials and methods
Virus production and titration
rAAV2/6 was produced by cotransfection of the pAAV-
CMV shuttle plasmid coding for eGFP with the pDF6
packaging plasmid into the 293AAV cell line [42]. Cell
lysates were subjected to purification by high pressure liq-
uid chromatography on the HiTrap Heparin column (GE
Healthcare Bio-Sciences AB, Uppsala, Sweden) 48 hr later.
The obtained viral suspension was concentrated with Cen-
tricon Plus-20 (Regenerated Cellulose 100,000 MWCO
(Millipore, Billerica, MA)) and the suspension medium
replaced with PBS. The infectivity (transduction units per
volume) of the rAAV2/6 was determined by flow cytome-
try for direct eGFP fluorescence. The percentage of eGFP-
positive cells was quantified 48 hr after infection of 293T
cells with respect to uninfected control cells. The number
of transduction events was calculated using the Poisson
equation.
Animals and vector administration
All manipulations were performed in six-week-old male
C57BL/6 mice (Charles River Lab, L'Abresle, France)
except for the strain comparison experiment that also
used SJL and B6SJLF1 mice (Charles River Lab). All proce-
dures were approved by the Committee on Animal Exper-Molecular Pain 2009, 5:52 http://www.molecularpain.com/content/5/1/52
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imentation for the canton of Vaud, Switzerland, in
accordance with Swiss Federal Law on Animal Welfare
and the guidelines of the International Association for the
Study of Pain [43]. Animals were housed under a 12 h
light/dark cycle and had free access to food and water.
Vector injections were performed under anesthesia with
either ketamine-xylazine (120 mg/kg ketamine, 10 mg/kg
xylazine) or 1.5% isoflurane (Abott, Baar, Switzerland),
except intravenous injections which were performed with-
out anesthesia.
rAAV2/6 was injected through five different routes. For
intramuscular injections, an incision was made on the
lower leg to expose the triceps surae muscle and 30 L of
the vector were injected using a 30-gauge (30 G) Hamil-
ton syringe (Bonaduz, Switzerland). For subcutaneous
injections, 10 L of vector solution were injected in the
glabrous plantar skin territory of the left hindpaw using a
30 G Hamilton syringe. For sciatic nerve injections, an
incision was made on the thigh to expose the quadriceps
femoral muscles which were then carefully separated to
expose the nerve. The vector was manually delivered in 6
L using a 30 G Hamilton syringe after which the muscle
and skin were closed in two distinct layers with 5.0 silk
threads and wound clips, respectively. Three doses of virus
were used for the intramuscular, subcutaneous and sciatic
nerve delivery: 2.6 × 104, 8.0 × 104 and 2.6 × 105 tu of
rAAV2/6.
Intrathecal administration was performed in two parts
and used 2.6 × 105 tu of rAAV2/6. Mice were first anesthe-
tized with ketamine-xylazine and then placed vertically
with their head fixed in a stereotaxic frame. An incision
was made in the base of the neck to expose the groove in
the nuchal crest. An incision was made (1 - 2 mm) in the
cisternal membrane to a depth such that cerebrospinal
fluid leaked out. A 4 cm 32 G intrathecal catheter (Micor
CS-1, Micor Inc, Allison Park, PA, USA) was then slowly
inserted in the direction of the lumbar spinal cord and
skin was closed by suture around the catheter. The mice
were then allowed to recover. Any animals that presented
motor or gait disturbance 2 hr following the surgery were
sacrificed. In the second part, mice that did not present
motor abnormalities were anesthetized with isoflurane
and the vector (6 L) was administered. The catheter was
flushed with 6 L of PBS and was then removed and mice
allowed to recover. For intravenous injections, 200 L
containing 1.2 × 107 tu of the vector in PBS were injected
into the tail vein using a 25-gauge Terumo® syringe (Leu-
ven, Belgium). Control animals received PBS or no injec-
tion.
Spared nerve injury
Adult C57BL/6 mice were operated for SNI using 1.5%
isoflurane as described previously [44]. Briefly, after expo-
sure of the sciatic nerve, the common peroneal and tibial
nerves were ligated with 5.0 silk suture and transected
while the sural nerve was left intact. Muscle and skin were
closed in two distinct layers with 5.0 silk thread and
wound clips. Sham surgery was performed the same
although without nerve ligation. Mice were injected
intrathecally three days post-surgery with 2.6 × 105 tu of
rAAV2/6-eGFP and sacrificed for analysis three weeks
later.
Immunohistochemistry
Three weeks after injection, animals were terminally anes-
thetized with sodium pentobarbital and transcardially
perfused with saline, followed by 4% paraformaldehyde
in PBS. DRG and spinal cord segments were dissected and
post-fixed at 4°C for 90 min or 3 hr, respectively. Tissues
were then transferred to 20% sucrose in PBS overnight
and mounted on dry ice the following day in cryoembed-
ding fluid (Tissue-Tek; Sakura Finetek, Zoeterwoude, Hol-
land). Dissected DRG and spinal cords were cryosectioned
at 12 and 20 m thickness, respectively, and mounted
directly onto slides. The eGFP signal on spinal cord sec-
tions was increased using a rabbit anti-eGFP antibody
(1:500, Molecular Probes, CA). Direct eGFP or anti-eGFP
signals were colabeled using the following antibodies:
rabbit anti--calcitonin gene-related peptide (CGRP,
1:5000, Peninsula Laboratories, San Carlos, CA), rabbit
anti-vanilloid receptor subtype 1 (TRPV1; 1:200; gift from
GlaxoSmithKline, Middlesex, United Kingdom), rat anti-
Substance P (1:400, BD Bioscience, Basel, Switzerland),
mouse anti-neurofilament 200 (NF200, 1:500, Sigma,
Basel, Switzerland), rabbit anti-ionized calcium binding
adaptor molecule 1 (Iba1, 1:200, Wako Pure Chemical
Industries, Osaka, Japan) and rabbit anti-glial fibrillary
acidic protein (GFAP, 1:1000, DakoCytomation, Glos-
trup, Denmark). Primary antibodies were revealed by the
appropriate Cy3-conjugated secondary antibodies (1:300,
Jackson ImmunoResearch, Suffolk, UK). Non-peptidergic
neurons were labeled using biotinylated griffonia sim-
plicifolia Isolectin B4 (IB4) (1:200 in DRG, 1:50 in spinal
cord, Vector Laboratories, Burlingame, CA) coupled to
AMCA-conjugated Streptavidin (1:200; Jackson Immu-
noResearch). Except for the monoclonal NF200 antibody
that utilized the mouse-on-mouse (MOM) kit (Vector
Laboratories, Burlingame, CA), standard fluorescent
immunohistochemistry techniques were used for all pro-
tocols. Briefly, sections were blocked for 30 min at room
temperature in PBS 10% serum and 0.3% triton X-100
and then incubated overnight at 4°C with primary anti-
body or biotinylated IB4 diluted in PBS 5% serum and
0.1% Triton X-100. Sections were washed in PBS and
incubated for 90 min at room temperature with corre-
sponding Cy3-conjugated secondary antibody, or AMCA-
conjugated streptavidin, diluted in PBS serum 1% and
0.1% Triton X-100. Slides were then washed again andMolecular Pain 2009, 5:52 http://www.molecularpain.com/content/5/1/52
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mounted with Mowiol mounting medium (Calbiochem,
Gibbstown, NJ).
qPCR
Total DNA and RNA was isolated from tissues using QIA-
GEN DNA/RNA Mini Kit (QIAGEN, Valencia, CA). The
amount of vector genomes per cell for each tissue was
determined by qPCR with the iQ SYBR Green Supermix
(Bio-Rad, Hercules, CA) using standard conditions. Prim-
ers were targeted against the beta-globin intron of the
rAAV2/6 vector (forward, TCTTATCTTCCTCCCACAGC;
reverse, GTCACTCTTGGCACGGGGAA) and the mouse
chemokine (C-C) motif receptor 5 (CCR5) of the host
genome (forward, GTCCTCCTCCTGACCACCTTC;
reverse, GCAGCAGTGTGTCATTCCAAG). Vector
genomes copies for each sample were quantified accord-
ing to the plasmid standard curve and were expressed for
2N genomes according to the CCR5 copy number meas-
ured in the same sample as described previously [18]. The
relative levels of eGFP mRNA were quantified by reverse
transcription qPCR. Isolated RNA was used as a template
to generate cDNA via StrataScript® First-Strand Synthesis
System (Stratagene, La Jolla, CA). Relative amounts of
eGFP transcripts between different tissues was determined
by qPCR with primers targeting eGFP (forward, TGAC-
CCTGAAGTTCATCTGCACCA; reverse, TCTTGTAGTT-




performed using the 7900HT Fast Real Time PCR System
(Applied Biosystems Inc, Foster City, CA). Dissociation
curves confirmed amplification of solely one PCR product
for all qPCR reactions.
Counting and statistics
Direct eGFP fluorescence detection in whole DRG was
performed using an epifluorescent microscope (AxioPlan,
Zeiss, Feldbach, Switzerland). Scoring of DRG following
intrathecal injection was performed using the following
qualitative criteria (0 = zero, 1 = faint, 2 = weak, 3 = mod-
erate and 4 = intense eGFP expression). Colocalization
was performed using a Zeiss laser scanning confocal
microscope (LSM 510 Meta, Zeiss). L4 DRG from three to
four animals were analyzed per condition except for the
SNI evaluation that used both L4 and L5 DRG for the
quantification. To evaluate transduction rates, a slide
from the first 5 was randomly selected and then every fifth
DRG section was selected from the series of consecutive
serially cut sections (4 - 5 sections per DRG). In each
selected section, the number of direct eGFP fluorescent
cells was counted and transduction efficiency was
expressed as the percentage of the total cell number. To
construct profile size distribution histograms, we meas-
ured the area of eGFP-positive cells using the AxioVision
LE Rel.4.3 Software (Zeiss). Neurons were classified in
three groups: small (<300 m2), medium (300-700 m2)
and large (>700 m2) neurons as described previously
[20]. Data are represented as mean ± SEM. Differences
between groups were compared using Student's t test. Sta-
tistical analyses were performed using JMP statistical soft-
ware (version 5.01, SAS institute, Cary, NC). A P value 
0.05 was considered statistically significant.
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depicted with DAPI. Scale bar: 50 m.




eGFP expression in the spinal cord anterior horn following intrathecal 
and sciatic nerve delivery of 2.6 × 105 tu rAAV2/6. eGFP-positive cells 
have large cell bodies (> 25 m) and colocalize with CGRP. CGRP is 
expressed by a subset of motor neuron pools and is a non-specific marker 
for this cell type in the spinal cord. Scale bar: 100 m.




DRG transduction efficiency is not altered in the SNI mouse model of 
neuropathic pain. C57Bl/6 mice were intrathecally injected with rAAV2/
6 three days following nerve ligation in the spared nerve injury (SNI) 
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transduction rate was observed between sham and SNI-treated animals (n 
= 3 per group) (P = 0.52).
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